184 related articles for article (PubMed ID: 38032827)
1. Hormonal Medications for Genitourinary Syndrome of Menopause.
Pinkerton JV; Vaughan MH; Kaunitz AM
Clin Obstet Gynecol; 2024 Mar; 67(1):68-78. PubMed ID: 38032827
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
3. Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse.
Rahn DD; Richter HE; Sung VW; Hynan LS; Pruszynski JE
Am J Obstet Gynecol; 2023 Sep; 229(3):309.e1-309.e10. PubMed ID: 37244454
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
5. Treatment of the genitourinary syndrome of menopause.
Palacios S; Mejía A; Neyro JL
Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
[TBL] [Abstract][Full Text] [Related]
6. The urogenital system and the menopause.
Calleja-Agius J; Brincat MP
Climacteric; 2015; 18 Suppl 1():18-22. PubMed ID: 26366796
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
8. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.
Potter N; Panay N
Climacteric; 2021 Feb; 24(1):19-24. PubMed ID: 32990054
[TBL] [Abstract][Full Text] [Related]
9. Genitourinary Syndrome of Menopause.
Shifren JL
Clin Obstet Gynecol; 2018 Sep; 61(3):508-516. PubMed ID: 29787390
[TBL] [Abstract][Full Text] [Related]
10. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
Edwards D; Panay N
Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
[TBL] [Abstract][Full Text] [Related]
11. Treatment of dyspareunia secondary to vulvovaginal atrophy.
Fantasia HC
Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
[TBL] [Abstract][Full Text] [Related]
12. Ospemifene in the treatment of vulvovaginal atrophy.
Barnes KN; Pearce EF; Yancey AM; Forinash AB
Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
[TBL] [Abstract][Full Text] [Related]
13. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
Reid RL; Black D; Derzko C; Portman D
J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
[TBL] [Abstract][Full Text] [Related]
14. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
15. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
16. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
Portman DJ; Goldstein SR; Kagan R
Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
18. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
[TBL] [Abstract][Full Text] [Related]
19. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
Nappi RE; Panay N; Bruyniks N; Castelo-Branco C; De Villiers TJ; Simon JA
Climacteric; 2015 Apr; 18(2):233-40. PubMed ID: 25335119
[TBL] [Abstract][Full Text] [Related]
20. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
Pinkerton JV; Kagan R
Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
